RE:RE:RE:RE:The evidence is clearNice post hydrocq, I agree 100%.
over the years only a few I have ever put on ignore.
That actually was near Y2k, nothing to do with Onc.
while I have been following since inception, have posted on many other stocks.
Those individuals were attacking me personally. Rather than rebut, I just ignored.
regarding Onc progress etc.
your comments are right on.
They have failed various trials, yet lessons from failures.
The depth of Onc board, mangement & techical advisors is awesome.
again echoing your comments. They , nore Roche, Pfizer et. al. Would not risk their professional integrity withiut thorough investigation.
Most recent being the $5million grant from PanCan. That was part of massive DD on their part.
Many professionals, PhDs & cancer specialists, have faith in Pela, not to mention the FDA.
Yes it has been a very long road. The most recent ( last 6 months), have produced awesome potential.
Date of final details? As you said, before end of June.
keep in mind, very important.
The pancreatic phase 3 enforced by CGAR , includes Roche tecentriq.
No doubt, lots of discussions to be finalized. Those conversations will be revealed when the lawyers, accountants & FDA regulators , figure out the final details.
big picture?
yup....20+ years.
Now down to a few weeks.
The SP is hurting because of the 20+ years. Some say more of the same.
CGAR , did not exist 20 years ago.
Has Onc created the paradigm shift required to get Pela to market?
The answer will be known quite soon.
again, Roche would not risk their good name & lead product tecentriq, on a whim.
ill admit , the sooner we get the details the better.